BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3542325)

  • 1. Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy.
    Osoba D; Erlichman C; Willan AR; Levitt M; Pater JL
    Clin Invest Med; 1986 Nov; 9(4):225-31. PubMed ID: 3542325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.
    Gralla RJ; Itri LM; Pisko SE; Squillante AE; Kelsen DP; Braun DW; Bordin LA; Braun TJ; Young CW
    N Engl J Med; 1981 Oct; 305(16):905-9. PubMed ID: 7024807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, cross-over study comparing prochlorperazine and lorazepam with high-dose metoclopramide and lorazepam for the control of emesis in patients receiving cytotoxic chemotherapy.
    Bishop JF; Wolf M; Matthews JP; Scott K; Ackland S; Yuen K; Morton C; Hillcoat BL; Cooper IA
    Cancer Treat Rep; 1987 Nov; 71(11):1007-11. PubMed ID: 3315193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
    Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
    Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose metoclopramide versus methylprednisolone in controlling chemotherapy induced nausea and vomiting.
    Chiara S; Scarsi P; Campora E; Bruzzi P; Tatarek R; Rosso R
    Chemioterapia; 1984 Oct; 3(5):333-6. PubMed ID: 6398127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
    Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
    J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metoclopramide, methylprednisolone and flunitrazepam in cytostatic-induced vomiting].
    Joss R; Rohrbach D; Pirovino M; Bischoff A; Kiser J; Brunner K
    Schweiz Med Wochenschr; 1987 Dec; 117(52):2113-7. PubMed ID: 3433092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
    Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
    Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
    Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Randomized cross-over study on the effects of methylprednisolone, metoclopramide and droperidol on the control of nausea and vomiting associated with cis-platinum chemotherapy].
    Niijima T; Isurugi K; Akaza H; Kondo Y; Kawabe K; Fujita K; Koiso K; Yokoyama M; Kinoshita K; Aso Y
    Gan To Kagaku Ryoho; 1986 Jul; 13(7):2376-82. PubMed ID: 3729492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
    Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure of methylprednisolone acetate to prolong the antinauseant effect of intravenous methylprednisolone sodium succinate in patients receiving chemotherapy.
    Osoba D; Erlichman C; Willan AR; Brigden ML; Geggie P; Pater JL; Rusthoven JJ; Wilson KS
    Clin Invest Med; 1988 Oct; 11(5):377-9. PubMed ID: 3052974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
    Coiffier B; Khayat D; Misset JL; Votan B
    Bull Cancer; 1997 Aug; 84(8):781-7. PubMed ID: 9339181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High dose metoclopramide during cancer chemotherapy. Phase II study in 80 consecutive patients].
    Bui NB; Marit G; Albin H; Durand M; Mauriac L; Hoerni B
    Bull Cancer; 1982; 69(4):330-5. PubMed ID: 7150789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Randomized crossover trial of the antiemetic effects obtained with metoclopramide and droperidol versus those obtained with metoclopramide, droperidol and methylprednisolone in patients receiving cis-platinum chemotherapy].
    Fujii M; Kiura K; Tamai M; Okabe K; Toki H
    Gan To Kagaku Ryoho; 1986 Aug; 13(8):2562-7. PubMed ID: 3527070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.
    Ekert H; Waters KD; Jurk IH; Mobilia J; Loughnan P
    Med J Aust; 1979 Dec; 2(12):657-9. PubMed ID: 231736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
    Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
    J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.